Stephane Gesta Ph.D.
Vice President of R & D and Science Strategy
Stephane Gesta, Ph.D. is Vice President of Research & Development and Science Strategy at Berg. Dr Gesta joined Berg in 2011 and drives the company’s preclinical programs into IND filing and first in human studies. He focuses on translating Berg’s flagship Interrogative Biology® target discoveries into drug development programs in Oncology and Neurology, by overseeing the preclinical development strategy and communicating a vision and plan for clinical development. Dr Gesta leads a team of scientists in oncology, neurology, pharmacology and assay development and manages R&D collaborations with strategic academic partners to ensure maximal portfolio impact.
Dr Gesta received a Master’s degree in Cellular Biology and Physiology from the University Paul Sabatier in Toulouse, France, where he developed a passion for understanding human physiology and pathophysiology at the whole-body, system, organ, cellular, and molecular level, to treat diseases with unmet needs. Dr Gesta received a Ph.D. in Molecular and Cellular Pharmacology from the University Paul Sabatier, after studying adrenergic receptivity regulating paracrine function of adipose tissue in obese patients. He completed his postdoctoral training at the Joslin Diabetes Center in Boston where he was a Research Associate Fellow. He also served as an Instructor of Medicine at Harvard Medical School in Boston. Dr Gesta’s work has been published in top tier journals and presented at numerous international conferences. He holds several international patent applications on treatments for cancer, Parkinson’s disease, diabetes and obesity.